127 related articles for article (PubMed ID: 986241)
1. Hypoxia-dependent reduction of 1-(2-nitro-1-imidazolyl)-3-methoxy-2-propanol by Chinese hamster ovary cells and KHT tumor cells in vitro and in vivo.
Varghese AJ; Gulyas S; Mohindra JK
Cancer Res; 1976 Oct; 36(10):3761-5. PubMed ID: 986241
[TBL] [Abstract][Full Text] [Related]
2. In vivo testing of hypoxic radiosensitizers using the KHT murine tumour assayed by the lung-colony technique.
Rauth AM; Kaufman K
Br J Radiol; 1975 Mar; 48(567):209-20. PubMed ID: 1125550
[TBL] [Abstract][Full Text] [Related]
3. Characteristics of the metabolism-induced binding of misonidazole to hypoxic mammalian cells.
Chapman JD; Baer K; Lee J
Cancer Res; 1983 Apr; 43(4):1523-8. PubMed ID: 6831401
[TBL] [Abstract][Full Text] [Related]
4. Preclinical evaluation of the fluorinated 2-nitroimidazole N-(2-hydroxy-3,3,3-trifluoropropyl)-2-(2-nitro-1-imidazolyl) acetamide (SR-4554) as a probe for the measurement of tumor hypoxia.
Aboagye EO; Maxwell RJ; Kelson AB; Tracy M; Lewis AD; Graham MA; Horsman MR; Griffiths JR; Workman P
Cancer Res; 1997 Aug; 57(15):3314-8. PubMed ID: 9242466
[TBL] [Abstract][Full Text] [Related]
5. Novel fluorinated hypoxia-targeted compounds as Non-invasive probes for measuring tumor-hypoxia by 19F-magnetic resonance spectroscopy (19F-MRS).
Papadopoulou MV; Ji M; Bloomer WD
Anticancer Res; 2006; 26(5A):3253-8. PubMed ID: 17094437
[TBL] [Abstract][Full Text] [Related]
6. BRU59-21, a second-generation 99mTc-labeled 2-nitroimidazole for imaging hypoxia in tumors.
Melo T; Duncan J; Ballinger JR; Rauth AM
J Nucl Med; 2000 Jan; 41(1):169-76. PubMed ID: 10647620
[TBL] [Abstract][Full Text] [Related]
7. Binding to cellular macromolecules as a possible mechanism for the cytotoxicity of misonidazole.
Varghese AJ; Whitmore GF
Cancer Res; 1980 Jul; 40(7):2165-9. PubMed ID: 6155991
[TBL] [Abstract][Full Text] [Related]
8. 9-[3-(2-Nitro-1-imidazolyl)propylamino]-cyclopenteno[b]quinoline hydrochloride (NLCPQ-1). A novel DNA-affinic bioreductive agent as cytotoxin and radiosensitizer.
Papadopoulou MV; Ji M; Rao MK; Bloomer WD
Oncol Res; 1996; 8(10-11):425-34. PubMed ID: 9114435
[TBL] [Abstract][Full Text] [Related]
9. Comparisons among pimonidazole binding, oxygen electrode measurements, and radiation response in C3H mouse tumors.
Raleigh JA; Chou SC; Arteel GE; Horsman MR
Radiat Res; 1999 May; 151(5):580-9. PubMed ID: 10319731
[TBL] [Abstract][Full Text] [Related]
10. Cytological effects of 1-(2-nitro-1-imidazolyl)-3-methoxy-2-propanol (misonidazole) on hypoxic mammalian cells in vitro.
Geard CR; Povlas SF; Astor MB; Hall EJ
Cancer Res; 1978 Mar; 38(3):644-9. PubMed ID: 626969
[TBL] [Abstract][Full Text] [Related]
11. Preclinical development and current status of the fluorinated 2-nitroimidazole hypoxia probe N-(2-hydroxy-3,3,3-trifluoropropyl)-2-(2-nitro-1-imidazolyl) acetamide (SR 4554, CRC 94/17): a non-invasive diagnostic probe for the measurement of tumor hypoxia by magnetic resonance spectroscopy and imaging, and by positron emission tomography.
Aboagye EO; Kelson AB; Tracy M; Workman P
Anticancer Drug Des; 1998 Sep; 13(6):703-30. PubMed ID: 9755726
[TBL] [Abstract][Full Text] [Related]
12. Potential Radiosensitizing Agents III: 2-Nitro-4-acetylimidazole analogs.
Sehgal RK; Agrawal KC
J Pharm Sci; 1982 Nov; 71(11):1203-6. PubMed ID: 7175708
[TBL] [Abstract][Full Text] [Related]
13. Direct relationship between radiobiological hypoxia in tumors and monoclonal antibody detection of EF5 cellular adducts.
Lee J; Siemann DW; Koch CJ; Lord EM
Int J Cancer; 1996 Jul; 67(3):372-8. PubMed ID: 8707411
[TBL] [Abstract][Full Text] [Related]
14. Toxicity of RSU-1069 for KHT cells treated in vivo or in vitro: evidence for a diffusible toxic product.
Hill RP; Gulyas S; Whitmore GF
Int J Radiat Oncol Biol Phys; 1989 Apr; 16(4):1111-4. PubMed ID: 2703391
[TBL] [Abstract][Full Text] [Related]
15. A comparison of the effectiveness of NF-167 and metronidazole as hypoxic cell sensitizers of KHT tumor cells in vitro.
Thomson JE; Rauth AM
Radiat Res; 1974 Dec; 60(3):489-500. PubMed ID: 10881726
[No Abstract] [Full Text] [Related]
16. Development of bioreductive markers for tumour hypoxia.
Hodgkiss RJ; Webster L; Wilson GD
Acta Oncol; 1995; 34(3):351-5. PubMed ID: 7779422
[TBL] [Abstract][Full Text] [Related]
17. Nitroimidazole-based bioreductive compounds bearing a quinazoline or a naphthyridine chromophore.
Papadopoulou MV; Bloomer WD
Anticancer Drugs; 2009 Jul; 20(6):493-502. PubMed ID: 19430289
[TBL] [Abstract][Full Text] [Related]
18. Increased cell killing by metronidazole and nitrofurazone of hypoxic compared to aerobic mammalian cells.
Mohindra JK; Rauth AM
Cancer Res; 1976 Mar; 36(3):930-6. PubMed ID: 1253180
[TBL] [Abstract][Full Text] [Related]
19. Toxicity of nitro compounds toward hypoxic mammalian cells in vitro: dependence on reduction potential.
Adams GE; Stratford IJ; Wallace RG; Wardman P; Watts ME
J Natl Cancer Inst; 1980 Mar; 64(3):555-60. PubMed ID: 6928241
[TBL] [Abstract][Full Text] [Related]
20. Differences in the toxicity and metabolism of the 2-nitroimidazole misonidazole (Ro-07-0582) in HeLa and Chinese hamster ovary cells.
Taylor YC; Rauth AM
Cancer Res; 1978 Sep; 38(9):2745-52. PubMed ID: 679180
[No Abstract] [Full Text] [Related]
[Next] [New Search]
